Sorafenib Tosylate (CAS 84461-73-0) Product Guide
Table of Contents
- Product Overview & Specifications
- Applications & Clinical Usage
- Case Studies
- Client Success Stories
- Contact for Quotation
Product Overview & Specifications
| Parameter | Sorafenib Tosylate | Regorafenib | Sunitinib |
|---|---|---|---|
| CAS Number | 84461-73-0 | 755037-03-7 | 557795-19-4 |
| Molecular Formula | C₂₁H₁₆ClF₃N₄O₃·C₇H₈O₃S | C₂₁H₁₅ClF₄N₄O₃ | C₂₂H₂₇FN₄O₂ |
| Therapeutic Targets | VEGFR, PDGFR, RAF | VEGFR1-3, TIE2 | VEGFR, PDGFR, c-KIT |
| Solubility | ≥10 mg/mL in DMSO | ≥5 mg/mL in DMSO | ≥20 mg/mL in DMSO |
Applications & Clinical Usage
Primary Indications:
- Advanced hepatocellular carcinoma (first-line treatment)
- Metastatic renal cell carcinoma
- Radioiodine-resistant thyroid cancer
Mechanism of Action:
Multikinase inhibitor targeting tumor proliferation (RAF/MEK/ERK pathway) and angiogenesis (VEGFR-2/3, PDGFR-β).
Case Studies
Case 1: HCC Treatment Protocol
Patient Profile: 58-year-old male with Child-Pugh A cirrhosis
Dosage: 400mg bid until disease progression
Outcome: 6.5 months progression-free survival
Client Success Stories
Oncology Center of Berlin (Germany)
– Annual procurement: 15kg
– Application: Clinical trials for combination therapy
– Feedback: “Consistent 99.2% HPLC purity across 12 batches”
Shanghai Pharma Co., Ltd (China)
– Usage: Generic drug development
– Batch consistency: RSD of 0.18% in potency testing
– Scale-up success: 500kg production validation
Contact for Quotation
Email: info@vivalr.com
Tel: (86) 15866781826
Request parameters: Required quantity, purity grade (USP/EP), packaging specifications



评论
目前还没有评论。